Investigator-Initiated (Pharmaceutical Industry)

Bristol-Myers Squibb –“Aripiprazole in Children with Symptoms of Mania” (Principal Investigator; 11/1/03-10/31/08)

Bristol-Myers Squibb – “Aripiprazole in At-Risk Children with Symptoms of Bipolar Disorder (Principal Investigator; 11/103-10/31/08)

AstraZeneca – “Quetiapine safety, effectiveness, and pharmacokinetics in children with conduct disorder” (Principal Investigator; 2002-2004)

GlaxoSmithKline – “The Mood Disorder Questionnaire in Children and Adolescents” (Principal Investigator; 2002-2003)

Pharmaceutical Industry Grants/Contracts (Industry – Initiated)

Novartis – “A Multicenter, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Trileptal® (Oxcarbazepine) in the Treatment of Children and Adolescents with Bipolar Disorder Type I” (Site Co-Principal Investigator and Clinician-in-Charge; 2003-2004)

Abbott Laboratories – “Evaluation of the Pharmacokinetic Profile and Safety of Depakote Extended-Release Tablets in Pediatric Patients” (Site Co-Principal Investigator and Clinician-in-Charge; 2001-2002)